JP Morgan Chase
PYXS icon

JP Morgan Chase’s Pyxis Oncology PYXS Stock Holding History

JP Morgan Chase’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.57K Sell
5,173
-341
-6% -$514 ﹤0.01% 6839
2025
Q4 		$6.34K Buy
5,514
+1,001
+22% +$3.53K ﹤0.01% 6772
2025
Q3 		$10K Buy
4,513
+2,445
+118% +$3.52K ﹤0.01% 6640
2025
Q2 		$2.27K Sell
2,068
-26,067
-93% -$29.4K ﹤0.01% 6521
2025
Q1 		$27.6K Buy
28,135
+1,059
+4% +$1.41K ﹤0.01% 6052
2024
Q4 		$42.2K Buy
27,076
+5,099
+23% +$14.7K ﹤0.01% 6078
2024
Q3 		$80.7K Buy
21,977
+665
+3% +$2.33K ﹤0.01% 5788
2024
Q2 		$70.5K Buy
21,312
+20,812
+4,162% +$87.5K ﹤0.01% 5704
2024
Q1 		$2.13K Hold
500
– – ﹤0.01% 6572
2023
Q4 		$900 Hold
500
– – ﹤0.01% 6848
2023
Q3 		$995 Sell
500
-3,813
-88% -$8.84K ﹤0.01% 6646
2023
Q2 		$11K Sell
4,313
-720
-14% -$2.28K ﹤0.01% 6040
2023
Q1 		$20K Buy
+5,033
New +$10.1K ﹤0.01% 5976
2022
Q2 		– Sell
-4,986
Closed -$20K – 6798
2022
Q1 		$20K Sell
4,986
-6,783
-58% -$49.6K ﹤0.01% 6071
2021
Q4 		$129K Buy
+11,769
New +$135K ﹤0.01% 5572

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase's PYXS Position: Q1 2026 in Review

JP Morgan Chase reduced its Pyxis Oncology (PYXS) stake by 6.2% in Q1 2026, selling an estimated $514 and leaving 5,173 shares worth $6.57K. The position accounts for ﹤0.01% of the portfolio, ranked #6839.

JP Morgan Chase first reported a position in PYXS in Q4 2021 and has held it in 15 quarters since. The position peaked at $129K in Q4 2021. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • JP Morgan Chase held 5,173 shares of Pyxis Oncology worth $6.57K as of Q1 2026.
  • JP Morgan Chase sold 341 Pyxis Oncology shares in Q1 2026, an estimated $514.
  • Pyxis Oncology made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6839 holding.
  • JP Morgan Chase first reported a position in Pyxis Oncology in Q4 2021 and has held it in 15 quarters since.
  • JP Morgan Chase's Pyxis Oncology position peaked at $129K in Q4 2021.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.